Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARGETALLO
NCT06992934Not yet recruiting
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Sep 2026
- Primary completion
- Aug 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Single-arm trial of gilteritinib in acute myeloid leukemia (AML), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoints: Phenotype of immunity cells at 1 year, Function of immunity cells at 1 year and 1 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
gilteritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06992934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06992934.